4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > MedKoo/CHIR-1241/100mg/406341
商品详细MedKoo/CHIR-1241/100mg/406341
MedKoo/CHIR-1241/100mg/406341
MedKoo/CHIR-1241/100mg/406341
商品编号: 406341
品牌: MedKoo
市场价: ¥25000.00
美元价: 15000.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

CHIR-124
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:406341

CAS#:405168-58-3

Description:CHIR-124 is a quinolone-based small molecule Chk1 inhibitor, that is structurally unrelated to other known inhibitors of Chk1. It potently and selectively inhibits Chk1 in vitro (IC(50) = 0.0003 micromol/L). CHIR-124 interacts synergistically with topoisomerase poisons (e.g., camptothecin or SN-38) in causing growth inhibition in several p53-mutant solid tumor cell lines as determined by isobologram or response surface analysis. CHIR-124 is a novel and potent Chk1 inhibitor with promising antitumor activities when used in combination with topoisomerase I poisons.

Price and Availability

SizePriceShipping out timeQuantity
100mgUSD 12502 Weeks
200mgUSD 19502 Weeks
500mgUSD 26502 Weeks
1gUSD 36502 Weeks
2gUSD 49502 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

CHIR-124 purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406341Name: CHIR-124CAS#: 405168-58-3Chemical Formula: C23H22ClN5OExact Mass: 419.15129Molecular Weight: 419.91Elemental Analysis: C, 65.79; H, 5.28; Cl, 8.44; N, 16.68; O, 3.81

Synonym:CHIR124; CHIR-124; CHIR 124.

IUPAC/Chemical Name:3-(1H-benzo[d]imidazol-2-yl)-6-chloro-4-((1R,3S,4R)-quinuclidin-3-ylamino)quinolin-2(1H)-one.

InChi Key:MOVBBVMDHIRCTG-LJQANCHMSA-N

InChi Code:InChI=1S/C23H22ClN5O/c24-14-5-6-16-15(11-14)21(25-19-12-29-9-7-13(19)8-10-29)20(23(30)28-16)22-26-17-3-1-2-4-18(17)27-22/h1-6,11,13,19H,7-10,12H2,(H,26,27)(H2,25,28,30)/t19-/m1/s1

SMILES Code:O=C1NC2=C(C=C(Cl)C=C2)C(N[C@@H]3C[N@]4CC[C@]3([H])CC4)=C1C5=NC6=CC=CC=C6N5

Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not soluble in water.

Shelf Life:
>2 years if stored properly.

Drug Formulation:
CHIR-124 may be formulated in DMSO.

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

References

1: Dufau I, Frongia C, Sicard F, Dedieu L, CordelierP, Ausseil F, Ducommun B, Valette A. Multicellular tumor spheroid modelto evaluate spatio-temporal dynamics effect of chemotherapeutics:application to the gemcitabine/CHK1 inhibitor combination in pancreaticcancer. BMC Cancer. 2012 Jan 13;12:15. doi: 10.1186/1471-2407-12-15.PubMed PMID: 22244109; PubMed Central PMCID: PMC3280152.

2: Lee JH, Choy ML, Ngo L, Venta-Perez G, Marks PA. Role of checkpointkinase 1 (Chk1) in the mechanisms of resistance to histone deacetylaseinhibitors. Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19629-34. doi:10.1073/pnas.1117544108. Epub 2011 Nov 21. PubMed PMID: 22106282; PubMedCentral PMCID: PMC3241758.

3: Tao Y, Leteur C, Yang C, Zhang P, Castedo M, Pierré A, Golsteyn RM,Bourhis J, Kroemer G, Deutsch E. Radiosensitization by Chir-124, aselective CHK1 inhibitor: effects of p53 and cell cycle checkpoints.Cell Cycle. 2009 Apr 15;8(8):1196-205. Epub 2009 Apr 16. PubMed PMID:19305158.

4: Seiler JA, Conti C, Syed A, Aladjem MI, Pommier Y. The intra-S-phasecheckpoint affects both DNA replication initiation and elongation:single-cell and -DNA fiber analyses. Mol Cell Biol. 2007Aug;27(16):5806-18. Epub 2007 May 21. PubMed PMID: 17515603; PubMedCentral PMCID: PMC1952133.

5: Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, Ma S,Moler EJ, Ni ZJ, Lopes de Menezes DE, Hibner B, Gesner TG, Schwartz GK.CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicityof topoisomerase I poisons in vitro and in vivo. Clin Cancer Res. 2007Jan 15;13(2 Pt 1):591-602. PubMed PMID: 17255282.

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。